The approval of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in the second-line (2L) setting for large B-cell lymphoma (LBCL) has reshaped tr…

Johnson & Johnson has dropped a pair | Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north of $5 billion.

There have been 733 cases so far this year, a CDC report said.

Brian Shaffer, MD, previews a session on cyclophosphamide, gut microbiota and T-cell depleted transplantation.

T cells are the central drivers of many inflammatory diseases, but the repertoire of tissue-resident T cells at sites of pathology in human organs remains poorly understood. We examined the site-specificity of T cell receptor (TCR) repertoires across tissues (5 to 18 tissues per patient) in prospect …

The historic clinical trial is a global effort between Obafemi Awolowo University, Lagos University Teaching Hospital, and Medserve in Nigeria and Memorial Sloan Kettering Cancer Center in the United ...

Population-scale WGS reveals genetic determinants of persistent EBV DNA, linking immune regulation—especially antigen processing and MHC class II variation—to EBV persistence and heterogeneous di...

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of C...

Some students who remain unvaccinated are now in a second 21-day quarantine since the beginning of the school year.

When Dr. Urvi Shah was diagnosed with Hodgkin lymphoma in 2016 during her first year as a hematology-oncology fellow, she heard lots of recommendations from friends and family about what she should an...